Stock listing

KRX:084650 LabGenomics Co., Ltd. (랩지노믹스) 주가

Follow LabGenomics Co., Ltd. into a list and get an email when it puts out news.

Share price · KRX:084650

₩1,958.00 KRW +85.00 (+4.5%)

Close on Nov 20, 2026

Past year -82.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩1,896.00 – ₩1,994.00 KRWNov 20, 2026
Volume
26,479 sharesNov 20, 2026
Market cap
₩17.77B KRWAt the close on Nov 20, 2026 · price × 9.08M shares outstanding
52-week range
₩1,500.00 – ₩11,375.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩265.4M KRWMedian day 55,311 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
LabGenomics Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:084650 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩1,958.00+85.00+4.5%₩1,896.00₩1,994.00₩1,896.0026,479
₩1,873.00+39.00+2.1%₩1,834.00₩1,873.00₩1,745.0034,675
₩1,834.00-30.00-1.6%₩1,864.00₩1,915.00₩1,710.0029,859
₩1,864.00-121.00-6.1%₩2,040.00₩2,040.00₩1,861.0050,401
₩1,985.000.000.0%₩1,972.00₩2,015.00₩1,972.0040,526
₩1,985.00-14.00-0.7%₩1,958.00₩2,020.00₩1,955.0045,589
₩1,999.00+99.00+5.2%₩1,900.00₩2,030.00₩1,900.0056,490
₩1,900.00+28.00+1.5%₩1,890.00₩1,964.00₩1,852.0085,467
₩1,872.00-22.00-1.2%₩1,885.00₩1,903.00₩1,815.0042,699
₩1,894.00-14.00-0.7%₩1,900.00₩1,930.00₩1,817.0035,615
₩1,908.00+88.00+4.8%₩1,838.00₩1,930.00₩1,824.0066,697
₩1,820.00+8.00+0.4%₩1,812.00₩1,850.00₩1,724.0059,503
₩1,812.00-93.00-4.9%₩1,905.00₩1,905.00₩1,799.0057,617
₩1,905.00-190.00-9.1%₩2,045.00₩2,075.00₩1,770.0085,525
₩2,095.00+85.00+4.2%₩2,010.00₩2,095.00₩1,913.0046,256
₩2,010.00-5.00-0.2%₩2,035.00₩2,065.00₩1,870.00102,693
₩2,015.00+165.00+8.9%₩1,851.00₩2,055.00₩1,851.00138,170
₩1,850.00+81.00+4.6%₩1,769.00₩1,903.00₩1,769.0081,768
₩1,769.00+69.00+4.1%₩1,785.00₩1,801.00₩1,666.00167,696
₩1,700.00+70.00+4.3%₩1,630.00₩1,878.00₩1,500.00723,686
₩1,630.00-665.00-29.0%₩2,305.00₩2,325.00₩1,630.00652,684
₩2,295.00-65.00-2.8%₩2,330.00₩2,450.00₩2,260.0049,243
₩2,360.00-90.00-3.7%₩2,495.00₩2,500.00₩2,350.0017,316
₩2,450.00+10.00+0.4%₩2,360.00₩2,480.00₩2,360.0011,090
₩2,440.00+135.00+5.9%₩2,395.00₩2,450.00₩2,285.0034,208
₩2,305.00-140.00-5.7%₩2,260.00₩2,435.00₩2,260.0048,030
₩2,445.00-55.00-2.2%₩2,500.00₩2,595.00₩2,445.0025,239
₩2,500.00-70.00-2.7%₩2,465.00₩2,565.00₩2,455.0060,430
₩2,570.00-205.00-7.4%₩2,655.00₩2,750.00₩2,570.0047,243
₩2,775.00-110.00-3.8%₩2,760.00₩2,850.00₩2,700.0060,004
₩2,885.00+210.00+7.9%₩2,740.00₩3,190.00₩2,725.00543,057
₩2,675.00+20.00+0.8%₩2,780.00₩2,780.00₩2,615.0046,334
₩2,655.00-115.00-4.2%₩2,770.00₩2,795.00₩2,650.0057,821
₩2,770.00+155.00+5.9%₩2,615.00₩2,825.00₩2,610.0082,226
₩2,615.00+90.00+3.6%₩2,580.00₩2,800.00₩2,580.0077,929
₩2,525.00-170.00-6.3%₩2,500.00₩2,680.00₩2,500.0060,237
₩2,695.00-230.00-7.9%₩2,880.00₩2,880.00₩2,665.00174,630
₩2,925.00+425.00+17.0%₩2,500.00₩3,040.00₩2,490.00789,606
₩2,500.00-295.00-10.6%₩2,750.00₩2,790.00₩2,495.0076,198
₩2,795.00-210.00-7.0%₩2,960.00₩3,195.00₩2,795.0054,132
₩3,005.00-30.00-1.0%₩3,005.00₩3,070.00₩2,990.0017,111
₩3,035.00+30.00+1.0%₩3,010.00₩3,085.00₩2,955.0016,261
₩3,005.00-60.00-2.0%₩3,000.00₩3,140.00₩2,865.0034,641
₩3,065.00+140.00+4.8%₩3,100.00₩3,590.00₩3,050.00237,086
₩2,925.00-175.00-5.6%₩3,040.00₩3,095.00₩2,920.0017,728
₩3,100.00+40.00+1.3%₩3,195.00₩3,505.00₩3,050.0036,663

Splits

4 splits since 2016 · KRX:084650 · every price before a split is adjusted for it

DayRatioWhat
1-for-5Consolidation
2-for-1Split
3-for-1Split
2-for-1Split
Ticker
KRX:084650
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
KRX
Currency
KRW

LabGenomics Co., Ltd. on 6ix

Sector
Health care
Industry
Diagnostics & research services

Valuation

EV/sales 0.0× against a median of 2.0×: the lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩3.46B KRW
P/E
Loss
EV/sales
0.0×
EV/EBITDA
Negative EBITDA
Price/book
0.1×
Gross margin
34.1%
Operating margin
−49.8%
Net margin
−66.5%
Debt to equity
0.1×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
LabGenomics Co., Ltd. · KRX:084650US$13.28MUS$2.59Mn/a0.0×n/a0.1×−66.5%0.1×n/a
Biosynex SA · EURONEXT:ALBIOUS$15.37MUS$73.75Mn/a0.7×2.3×0.4×−61.1%1.9×n/a
Verici DX PLC · LSE:VRCIUS$15.25MUS$13.61Mn/a3.6×n/a2.6×−189.2%0.1×n/a
Medicon Hellas · ATHEX:MEDICUS$14.99MUS$7.66M7.7×0.4×1.9×0.7×9.8%0.0×n/a
Pharmigene, Inc. · TPEX:7595US$14.70MUS$29.38Mn/a4.8×n/a1.9×−36.5%2.2×n/a
BCAL Diagnostics Limited · ASX:BDXUS$14.64MUS$18.17Mn/a150×n/an/an/an/an/a
Rhythm Biosciences Limited · ASX:RHYUS$14.05MUS$11.94Mn/a211×n/a5.8×n/a0.1×n/a
Noul Co Ltd. · KRX:376930US$14.03MUS$6.23Mn/a1.6×n/a1.1×−389.6%0.0×n/a
Telescope Innovations Corp · CSE:TELIUS$13.52MUS$12.59Mn/a2.5×n/a5.7×−56.0%0.0×1.20
IDT Australia Limited · ASX:IDTUS$13.09MUS$18.52Mn/a1.4×n/a1.0×−13.4%0.6×n/a
Bionano Genomics, Inc. · NASDAQ:BNGOUS$11.50MUS$9.88Mn/a0.3×n/a0.4×−96.9%0.2×1.70
Median of the othersUS$14.35MUS$13.10M7.7×2.0×2.0×1.1×−58.6%0.1×1.45

Events

QuarterResultsShare move
Q4 2023Mar 28, 2024 · Before open−0.5%
Q4 2022Feb 13, 2023 · Before open−0.9%
Q3 2022Nov 14, 2022+2.9%
Q4 2021Feb 6, 2022 · After close+6.8%
Q3 2021Nov 1, 2021 · After close+1.5%
Quarter to Jun 30, 2021Aug 18, 2021 · Before open−0.2%
Quarter to Mar 31, 2021May 17, 2021 · After close+4.3%
Quarter to Dec 31, 2020Feb 8, 2021 · After close+1.6%

Open Events

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue88.2B85.9B71.1B144.8B202.4B119.5B33.2B27.5B24.8B24.1B
Cost of revenue57.5B54.5B40.7B48.0B77.0B47.7B19.8B18.1B15.3B13.3B
Gross profit30.6B31.4B30.4B96.8B125.4B71.7B13.4B9.44B9.46B10.8B
Research and development1.87B2.68B2.62B1.86B556.9M350.6M350.6M
Selling, general and administrative16.6B40.8B31.6B27.4B19.4B16.0B11.4B11.3B10.3B10.2B
Operating income-53.5B-21.6B-6.92B66.2B104.5B53.3B775.8M-3.23B-2.94B-8.48M
Depreciation and amortization10.3B6.03B4.45B3.56B3.34B3.43B3.80B1.38B1.29B1.32B
EBITDA-43.2B-15.6B-2.47B69.8B107.8B56.7B4.58B-1.85B-1.65B1.31B
Interest expense5.73B5.51B4.95B574.0M208.0M223.8M0000
Income before tax-60.3B-26.0B-7.13B63.4B109.1B51.8B1.08B-3.37B-4.30B139.0M
Income tax25.3B9.06B112.9M602.1M-866.5M-584.5M
Net income-64.4B-23.8B-4.67B48.4B83.9B42.8B962.4M-3.97B-3.44B723.5M
Earnings per share, basic-867.11-320.53-62.96711.901,258.171,259.0731.20-145.90-133.1728.35

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents6.76B24.5B42.3B354.0K282.0K37.8B2.00B399.1M495.4M2.66M
Short-term investments51.3B26.9B73.1B38.4B28.4B15.3B12.1B13.9B6.16B2.05B
Receivables11.6B38.0B37.1B35.3B68.4B31.5B18.4B16.1B14.6B11.8B
Inventory2.78B3.74B2.27B1.74B2.69B2.46B710.1M513.7M681.3M551.4M
Current assets74.5B135.6B160.4B174.5B170.9B87.5B33.6B31.4B22.2B24.7B
Property, plant and equipment57.4B55.0B54.9B19.7B7.99B7.44B6.52B6.63B6.38B
Goodwill55.6B58.3B54.9B1.00K1.00K1.00K1.00K1.00K1.00K1.00K
Total assets230.1B295.7B313.5B250.7B204.3B109.4B49.5B47.1B39.9B43.2B
Accounts payable10.1B9.65B9.29B6.56B11.4B8.09B4.21B3.87B3.82B3.65B
Current liabilities60.2B76.3B65.1B19.9B40.7B25.0B10.6B8.66B8.11B7.97B
Long-term debt13.1B016.0B19.2B3.20B06.21B6.55B8.67B9.09B
Total debt4.20B9.88B9.35B11.2B
Total liabilities80.5B79.3B85.3B41.3B46.6B27.8B19.1B17.0B17.5B18.2B
Shareholders' equity149.6B216.3B227.8B209.3B157.7B81.5B30.4B30.1B22.3B25.0B
Shares outstanding74.2M74.2M74.2M68.0M66.6M34.0M30.8M27.2M25.8M25.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-30.5B-13.0B2.42B69.9B65.4B46.4B3.19B608.0M-1.06B2.54B
Capital spending-1.66B-4.55B-5.20B-38.3B-13.7B-699.2M-560.9M-2.03B-4.30B-4.08B
Free cash flow-32.2B-17.5B-9.02B30.6B51.5B44.9B2.63B-1.42B-5.36B-1.53B
Cash from investing-3.76B-116.6B-53.3B-26.1B-8.59B-85.8M-10.6B-8.40B-5.32B
Cash from financing-2.23B57.6B11.4B-7.19B-959.8M-1.49B9.93B249.5M11.1B
Dividends paid0-3.32B
Share buybacks022.7B-6.54B331.6M-481.7M8.00B906.2M
Change in cash-17.7B-17.8B-56.2B28.0B32.7B35.8B1.60B-96.3M-9.21B8.37B

Open Financials

Cap table

Built by 6ix from LabGenomics Co., Ltd.’s releases

Common shares
9,076,740
Fully diluted
9,076,740

Fully diluted

LineShares
Common shares9,076,740

Share count over time

CountShares
Nov 22, 20269,076,740

Open Cap table

Shareholders

Open Shareholders

Log in to ask 6ix AI your own questions about LabGenomics Co., Ltd.